Meet the Team

Bjorn Millard, Ph.D.

Co-Founder and Head of Computational Biology

Bjorn started Residual Dynamics in 2021 with the belief that every drug program would benefit by applying the right computational method, at the right time, at the right step in the development process. This requires domain expertise, but also a dedication to integrate into the project team, getting hands on with the primary data, and developing an individualized strategy for each client. He has been a computational biologist for close to 15 years working both in computational consulting (Applied BioMath and RES Group Inc.) and directly as a team member for biotech companies (Merrimack Pharmaceuticals and Silver Creek Pharmaceuticals). He has expertise in predictive modeling and simulation, with many years directly implementing and analyzing Quantitative Systems Pharmacology (QSP) and semi-mechanistic-PK/PD models for pharmaceutical clients. The goals of these models include First-in-Human dose projections, drug property and dose regimen optimization, therapeutic window analysis, and preclinical experimental design. Bjorn studied Applied Mathematics and Neurobiology at the University of Washington in Seattle, and completed his Ph.D. in Systems Biology at Harvard University

Emily Pace, Ph.D.

Co-Founder and Head of Biology

Emily joined Residual Dynamics as Co-founder and Head of Biology in 2021. She brings 19+ years working on Discovery and Translational Research teams at companies, such as Bristol Myers Squibb (BMS), Applied BioMath, Celgene, and Merrimack Pharmaceuticals. Her work at the bench has covered early clinical development of a variety of drug modalities including cereblon modulators and bispecific antibodies. Most recently, Emily was employed at BMS working on the Immuno-Oncology & Cellular Therapy Late Stage research team leading preclinical translational research efforts for internal assets targeting an innate immune checkpoint axis. At Celgene, she supported early clinical investigations in Hematology and Oncology for a novel cereblon E3 ligase modulator. Her work as a Translational Scientist has provided mechanistic insights to support combinations for Phase I, identify potential biomarkers, help interpret clinical data, and execute patient sample analysis for First-in-Human clinical trials. On the computational side, Emily worked as a consultant at Applied BioMath, where she provided biological expertise for the design and development of QSP and semi-mechanistic PK/PD models by advising on modeling strategy and design, and by reviewing published and internal data to understand disease biology, drug properties and mechanism, and clinical findings. Emily completed her Ph.D. in Cell and Molecular Biology at Boston University